Journal
CELLS
Volume 10, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/cells10010039
Keywords
microRNA; hormone signaling; colorectal cancer; drug resistance
Categories
Funding
- VALERE: Vanvitelli per la Ricerca
- Campania Regional Government Technology Platform Lotta alle Patologie Oncologiche [iCURE-B21C17000030007]
- Campania RegionalGovernment [FASE2: IDEAL-B63D18000560007]
- MIUR [POC01_000 43-EPICUREPOC01_00043-B64I19000290008]
- POR Campania FSE 2014/2020 [ASSEIII-B27D18001070006]
- [AIRC-17217]
Ask authors/readers for more resources
Colorectal cancer (CRC) remains the third leading cause of cancer death globally, with patients often developing drug resistance and disease recurrence. Key studies have identified the crucial role of microRNAs (miRNAs) in cancer progression and drug resistance, suggesting their potential as future therapeutic targets for overcoming resistance in CRC treatment.
Despite substantial progress in cancer therapy, colorectal cancer (CRC) is still the third leading cause of cancer death worldwide, mainly due to the acquisition of resistance and disease recurrence in patients. Growing evidence indicates that deregulation of hormone signaling pathways and their cross-talk with other signaling cascades inside CRC cells may have an impact on therapy resistance. MicroRNAs (miRNAs) are small conserved non-coding RNAs thatfunction as negative regulators in many gene expression processes. Key studies have identified miRNA alterations in cancer progression and drug resistance. In this review, we provide a comprehensive overview and assessment of miRNAs role in hormone signaling pathways in CRC drug resistance and their potential as future targets for overcoming resistance to treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available